Loading...
Loading...
ATNF| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 0.0K |
| Gross Profit | 0.0K |
| Operating Expense | 5,639.9K |
| Operating I/L | -5,639.9K |
| Other Income/Expense | -17,045.1K |
| Interest Income | -4.6K |
| Pretax | -22,685.0K |
| Income Tax Expense | -942.7K |
| Net Income/Loss | -21,742.3K |
1180 Life Sciences Corp. is a clinical-stage biotechnology company specializing in the development of therapeutics for chronic pain, inflammation, fibrosis, and other inflammatory diseases. The company's product development platforms include fibrosis and anti-tumor necrosis factor (anti-TNF) platform, Synthetic Cannabidiol (CBD) Analogs platform, and a7nAChR platform. These platforms are at various stages of clinical and preclinical trials, focusing on addressing unmet medical needs. By advancing these platforms, the company aims to generate revenue through the commercialization of innovative therapies targeting chronic pain, inflammation, and fibrosis.
